PRMT7 restricts CD8+ T cells expansion via the NF-κB pathway.
Srour, N.; Luo, K.; Allard, D.; Xiong, Y.; Yu, Z.; Papadopoulos, T.; Santinon, F.; Hsieh, C.-H.; Stagg, J.; Barsyte-Lovejoy, D.; del Rincon, S. V.; Jin, J.; Richard, S.
Show abstract
New therapeutics are needed to enhance cytotoxic T lymphocyte (CTL) expansion and effector function for effective tumor control. Here, we show that T cell specific deletion of Prmt7 using CD4-Cre mice increases CD8+ effector differentiation, cytokine secretion, cytolytic activity, and anti-tumor responses. Prmt7 deficiency transcriptionally reprogrammed CD8+ T cells by activating the NF-{kappa}B pathway, boosting proliferation, and elevating effector molecules such as CD25, CD69, and IFN{gamma}. Mechanistically, PRMT7 associated with RelA and restricted its nuclear translocation. To enable therapeutic translation, we developed a PRMT7-targeting PROTAC degrader (MS54). MS54-treated CTLs exhibited NF-{kappa}B pathway activation similar to Prmt7-deficient CTLs. Adoptive transfer of MS54-treated OT-I CTLs significantly improved tumor control in a syngeneic melanoma model. In human CTLs, MS54 enhanced proliferation, activation markers (CD69, CD137), IFN{gamma} production, and cytotoxicity toward melanoma. Together, these findings identify PRMT7 as a negative regulator of CD8+ T cell immunity and highlight MS54 as a promising strategy to improve adoptive T cell therapy.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade 97%
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 95%
Similar papers in this journal
Similar papers in this journal
- Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy 96%
- Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity 96%
- Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases 95%
Similar papers in this journal
- Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity 95%
- De novo synthesis and salvage pathway coordinately regulates polyamine homeostasis and determines T cell proliferation and function. 95%
- TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function 94%
Similar papers in this journal
- T Lymphocyte-Specific Deletion of SHP1 and SHP2 Promotes Activation-Induced Cell Death of CD4+ T Cells and Impairs Antitumor Response 96%
- Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism 95%
- Galectin-9 binding to HLA-DR in dendritic cells controls immune synapse formation and T cell proliferation 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.